Weekly channel feed

FDA’s CAR-T safe­ty probe; Ab­b­Vie’s $10B ADC wa­ger; Pfiz­er’s GLP-1 set­back; Ace­lyrin’s CRO dra­ma; and more

Last year

Mer­ck­'s neu­ro-in­spired buy­out; Bay­er's bad week; One launch, one shut­down for Flag­ship; and more

Last year

Land­mark CRISPR ap­proval; Why don't in­vestors like Verve’s base edit­ing da­ta?; Janet Wood­cock to re­tire; Late Fri­day IPO fil­ing; and more

Last year

As­traZeneca leans in­to GLP-1; Cuts loom­ing at Bay­er; Eli Lil­ly’s obe­si­ty ap­proval; End­points Slack in­ter­view with Matt Gline; and more

Last year

Lat­est news on BioN­Tech's Fri­day buy­out; Un­pack­ing Sarep­ta’s Duchenne da­ta; Pfiz­er’s post-Covid plans; Eli Lil­ly, As­traZeneca's gene edit­ing deals; and more

Last year

Roche's $7.1B bet on Roivant drug; AD­Cs and oth­er #ES­MO23 dis­patch; High­lights from Alzheimer's con­fab; Q3 phar­ma dra­ma; and more

Last year

Mer­ck­'s big ADC move; Lat­est from #ES­MO23; How Eli Lil­ly is think­ing about deals; AI-de­signed drugs face reck­on­ing in clin­ic; and more

Last year

BMS buys Mi­rati for $4.8B; Pfiz­er to slash cost; Q&A with Ver­tex CSO; Al­ny­lam's On­pat­tro set­back; and more

Last year

Pi­o­neers of mR­NA win No­bel — plus our in­ter­view; Eli Lil­ly’s M&A, lead­er­ship shuf­fle; UniQure lay­offs as gene ther­a­py play­ers adapt; and more

Last year

Tak­ing pulse on pri­vate biotech fund­ing; Q&A with Iso­mor­phic Labs CEO; Re­search in­sti­tu­tions re­thinks deal­mak­ing; and more

Last year

The 2023 End­points 11; Re­gen­eron’s gene edit­ing am­bi­tions; GSK’s re­search re­vamp; Rip­ple ef­fect of Dana-Far­ber, Brigham breakup; and more

Last year

Mod­er­na's R&D game plan; 2sev­en­ty lay­offs amid CAR-T slow­down; Covid vac­cine boost­ers get thumbs up; and more

Last year

Biotech megarounds ga­lore; New lead­ers at No­var­tis, Bio­gen; State of play for GLP-1 in NASH; In­side Il­lu­mi­na’s CEO search; and more

Last year

The ne­go­ti­a­tions list is here; Am­gen, Hori­zon clear FTC hur­dle; Fall biotech IPOs?; No­vo buys biotech part­ner in obe­si­ty; and more

Last year

Rid­ing the wave on lat­est obe­si­ty buy­out; Slack in­ter­view with an­ti-ag­ing re­searcher; Two new IRA law­suits; and more

Last year

Re­gen­eron an­ti­body se­cures FDA win; Yan­copou­los in ex­pan­sive Q&A; Bio­gen’s Rea­ta bid­ding war de­tails re­vealed; Pe­ter Marks on ac­cel­er­at­ed ap­provals; and more

Last year

No­vo Nordisk and the fu­ture of obe­si­ty drugs; Ex­it Q&A with As­traZeneca's Mene Pan­ga­los; Il­lu­mi­na’s bad week; Lay­offs sweep biotech; and more

Last year

FDA clears Bio­gen, Sage's pill for post­par­tum de­pres­sion; What will Roivant, Bridge­Bio do next?; EQRx be­comes his­to­ry; Non-opi­oid pain drugs face piv­otal mo­ment; and more

Last year

Bio­gen's $7.3B M&A deal, lay­offs; R&D shake­up at Pfiz­er, As­traZeneca; Scal­ing rare dis­ease meds; Q2 earn­ings; and more

Last year

2023 Women in Bio­phar­ma R&D; Biotech hope­ful for re­bound even as new wave of lay­offs hit; No­var­tis' siR­NA buy­out; and more

Last year

Eli Lil­ly’s M&A Fri­day; No­var­tis' TIG­IT breakup; One big hire and one big ex­it; Re­verse merg­er, shut­down and white flags; and more

Last year

Alzheimer’s drug Leqem­bi gets full OK; Biotech’s H1 by the num­bers; Bring­ing Leerink back; Against AI over­hype; and more

Last year

Cell ther­a­py for di­a­betes: New da­ta, ap­proval, buy­out; GLP-1 race in weight loss reach­es new stage; FDA fi­nal­ly ap­proves Bio­Marin’s gene ther­a­py; and more

Last year

Sarep­ta's Duchenne gene ther­a­py wins OK; FDA spurns NASH drug; Eli Lil­ly buys DICE for $2.4B; The new an­titrust land­scape; and more

Last year
First page Previous page 1234567 Next page Last page
A service from the Financial Times